Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0MOGYS |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-NaPi-2b antibody |
|||||
| Antigen Name | NaPi-2b |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
XMT-1592 [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients (ECOG 0-1) must have measurable disease, adequate organ function, and provide tumor tissue for NaPi2b testing (fresh biopsy in expansion cohorts if feasible). Key exclusions: major surgery/systemic therapy within 28 days, untreated/progressive brain metastases, active infections (HIV/HBV/HCV), severe systemic illness (e.g., uncontrolled cardiovascular/pulmonary disease), prior auristatin/maytansinoid ADC treatment, or pregnancy. NSCLC and ovarian cancer (non-mucinous subtype) are specific cohorts.
Click to Show/Hide
|
||||
| Administration Dosage |
XMT-1592 will be administered once every 21 or 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04396340 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients With Solid Tumors Likely to Express NaPi2b
|
||||
| Primary Endpoint |
The study evaluates the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of XMT-1592 over 36 weeks, based on dose-limiting toxicities (DLTs) and adverse events, alongside concomitant medication use.
|
||||
| Other Endpoint |
Key pharmacokinetic parameters (Tmax, Cmax, AUC) are assessed daily for the first week, then weekly until 21 days post-dose, and before/after subsequent doses. Tumor response (RECIST 1.1) is monitored every 6 weeks, while anti-drug and neutralizing antibodies are analyzed every 3 weeks initially, then every 6 weeks up to 36 weeks.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04396340 | Clinical Status | Phase 1/2 | ||
| Clinical Description |
A phase 1b, first-in-human, dose escalation and expansion study of XMT-1592 in patients with solid tumors likely to express NAPI2B.
|
||||
References